SCHEMBL3340367

SCHEMBL3340367

CC(C)Oc1nc(N)nc2ccc(-c3ccc(C#N)cc3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.47
HRH4 Q9H3N8 2/20 0.46
SCN10A Q9Y5Y9 1/20 0.42
DHFR P00374 1/20 0.41
ADORA2A P29274 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
AAK1 Q2M2I8 4/20 0.38
CHEK1 O14757 1/20 0.38
GSK3B P49841 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38
BMP2K Q9NSY1 1/20 0.38
MAPKAPK2 P49137 1/20 0.37
SLC22A12 Q96S37 2/20 0.37
SYK P43405 1/20 0.37
ATM Q13315 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2C P18825 1/20 0.36
HTR1D P28221 1/20 0.36
HTR2A P28223 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341682 0.89 ADORA2A (0.53) MAP4K4HRH4ADORA2AATM
SCHEMBL3333937 0.85 DHFR (0.48) DHFRATM
SCHEMBL3333131 0.84 HSP90AB1 (0.47) HRH4DHFRADORA2AATM
SCHEMBL3337214 0.83 ATM (0.53) MAP4K4DHFRATM
SCHEMBL3338126 0.83 MAP4K4 (0.43) MAP4K4DHFRADORA2AATM
SCHEMBL3332604 0.83 AAK1 (0.44) MAP4K4DHFRAAK1CHEK1GSK3B
SCHEMBL3336166 0.83 ATM (0.39) DHFRATM
SCHEMBL3335845 0.80 ALOX5AP (0.40) MAP4K4DHFRATM
SCHEMBL3334043 0.80 MAP4K4 (0.45) MAP4K4DHFRADORA2AATM
SCHEMBL3337242 0.79 DHFR (0.48) DHFRATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 MAP4K4 2433/4885HRH4 18/4885SCN10A 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.